OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Huddart on the FDA Approval of Erdafitinib in FGFR3+ Urothelial Cancer

February 28th 2024

Robert Huddart, PhD, discusses the FDA approval of erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma.

Dr Grajales-Cruz on Benefit With Teclistamab in Select Patients With Relapsed/Refractory Myeloma

February 27th 2024

Ariel Grajales-Cruz, MD, discusses factors associated with benefit from teclistamab in heavily pretreated relapsed/refractory multiple myeloma.

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

February 27th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Dr Merchan on Key Data Supporting Pembrolizumab-Based Regimens in Advanced RCC

February 27th 2024

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRC

February 27th 2024

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant

February 24th 2024

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS

February 24th 2024

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

February 24th 2024

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies

February 24th 2024

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

February 23rd 2024

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

February 23rd 2024

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHD

February 23rd 2024

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.

Dr Kim on the Importance of the FDA Approval of Repotrectinib for ROS1+ NSCLC

February 23rd 2024

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

Dr Gross on the Background of Investigating Neoadjuvant Cemiplimab in CSCC

February 23rd 2024

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment Paradigm

February 22nd 2024

Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.

Dr Moustafa on Standard Treatment Approaches in MCL

February 22nd 2024

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.

Dr Jagsi on the Feasibility of Radiation Omission Following Surgery in Breast Cancer Care

February 22nd 2024

Reshma Jagsi, MD, DPhil, discusses 5-year findings from the IDEA trial assessing radiotherapy omission for postmenopausal patients with breast cancer.

Dr Park on the Rationale for the TROPHY-U-01 Trial in Urothelial Carcinoma

February 22nd 2024

Chandler H. Park, MD, FACP, discusses the rationale for evaluating sacituzumab govitecan plus pembrolizumab in metastatic urothelial carcinoma.

Dr Punekar on the Importance of Complete Biomarker Testing in Lung Cancer

February 22nd 2024

Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.

Dr Overman on the Potential Use of Endoscopy and ctNDA in Nonoperative GI Cancer Management

February 21st 2024

Michael J. Overman, MD, discusses the potential use of endoscopy and ctDNA to guide nonoperative management approaches in gastrointestinal cancers.